Huntington’s disease research news. In plain language. Written by scientists. For the global HD community.
The results are in from the Reach2HD study, which was designed to test the experimental drug PBT2 for early and mid-stage Huntington's disease. The drug seems safe and well-tolerated at the doses that were tested, but we have major concerns about the way the results have been reported.
Copper, the metal, may play a role in worsening the symptoms of Huntington’s disease. Bing Zhou and his team looked for connections between HD and the amount of copper in neurons. They report that reducing copper in neurons or keeping it from binding to the HD protein improves symptoms.
The Huntington Study Group and Prana Biotechnology are currently running a clinical trial, Reach2HD, to determine whether the drug PBT2 is effective in HD patients. Now, they've released the preclinical data behind the trial, showing the drug is effective in two animal models of HD.
Our second daily report from the European Huntington’s Disease Network 2012 Meeting in Stockholm. Video of both EuroBuzz evening sessions will be available to watch on HDBuzz.net next week.
Prana Biotech has announced a phase 2 clinical trial in Huntington's disease patients in Australia and the USA. Here's what we know so far about the trial, the company, the drug and the friendship between copper and the mutant huntingtin protein.